Impressions from EASD 2017

Caroline Day

Full Text:



Virtual meeting (abstracts, posters, webcasts). EASD, 2017.!resourcegroups/resourcetype_ids=1&event_ids=12

Abstracts of the 53rd EASD Annual Meeting, Lisbon, Portugal, 11–15 September 2017. Diabetologia 2017;60(Suppl 1):1–608.

EASD. Programme at a glance, 2017.

EASD. Final Programme of the 53rd EASD Annual Meeting, 2017. files/EASD_2017_Final%20Programme.pdf

60 years of metformin use: a glance at the past and a look to the future. Diabetologia Special Issue, September 2017, 107pp.

Campbell IW, Howlett HCS, Holman RR, Bailey CJ, eds. Metformin. 60 years of clinical experience. (Addendum to the Scientific Handbook). Weinheim, Germany: Wiley-VCH, 2017:122pp. ISBN 978-3-527-34449-9.

Bailey CJ, Campbell IW, Chan JCN, et al, eds. Metformin. The gold standard. (A Scientific Handbook). Chichester, UK: John Wiley & Sons, 2007:288pp. ISBN 987-0-470-72542-9).

Bailey C, Marshall S. Diabetes and metformin. EASD, 2017.

Petrie JR, Chatuverdi N, Ford I, et al, for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo- controlled trial. Lancet 2017;5:597–609.

REMOVAL: a randomized controlled trial of metformin in adults with type 1 diabetes. EASD, 2017.

Vaccaro O, Masulli M, Nicolucci A, et al, for the Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) Study Group. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017;5:887–97.

EXenatide Study of Cardiovascular Event Lowering (EXSCEL): primary results. EASD, 2017.!contentsessions/2628

Holman RR, Bethel MA, Mentz RJ, Thompson VP, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377: 1228–39.

Insulin degludec vs glargine: cardiovascular safety in type 2 diabetes: the DEVOTE study. EASD, 2017.!contentsessions/2613

Marso SP, McGuire DK, Zinman B, et al, for the DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723–32.

Neal B, Perkovic V, Mahaffey KW, et al, for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57.

CANagliflozin cardioVascular Assessment Study (CANVAS). EASD, 2017 (for amputations see Radholm K et al submitted- reported at EASD, 2017)!resources/canagliflozin-cardiovascular-assessment-study-canvas

Acarbose Cardiovascular Evaluation (ACE): primary results. EASD, 2017.!contentsessions/2631

Holman RR, Colemena RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:877–86.

Role of alirocumab in lipid management of individuals with type 1 and type 2 diabetes at high CV risk: ODYSSEY DM program. EASD, 2017.!contentsessions/2600

Leiter LA, Cariou B, Muller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 2017;19:1781–92.

Evolocumab in diabetes and diabetes risk: novelties from the FOURIER study. EASD, 2017.!contentsessions/2619

Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 14 September 2017 [Epub ahead of print]. 10.1016/S2213-8587(17)30313-3.

J-DOIT3: a multifactorial intervention trial for prevention of macrovascular complications and mortality. EASD, 2017.!contentsessions/2621

SGLT2 inhibitors: novel therapies for type 1 diabetes. EASD, 2017.!contentsessions/2606

Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3 randomised controlled trial. Lancet Diabetes Endocrinol 2017;5: 864–76.

An emerging and innovative therapeutic approach in type 1 diabetes with dual SGLT1 and SGLT2 inhibition: the Sotagliflozin Clinical Program. EASD, 2017.!contentsessions/2587

Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 13 September 2017 [Epub ahead of print]. 10.1056/NEJMoa1708337



  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists